NRAS and melanoma: We recently showed in another study that the lack of detection of ctDNA by qPCR Cobas (Roche diagnostics) at the initiation of first-line treatment was an independent factor of good prognosis, regardless of treatment (immunotherapy or targeted therapy) in BRAF or NRAS-mutated melanoma patients [16].